Ursodeoxycholic Acid Treatment in Patients with Primary Biliary Cirrhosis: A Swedish Multicentre, Double-Blind, Randomized Controlled Study

References

• Wiesner R H, LaRusso N F, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985; 88: 108–14
   PubMed Web of Science ®Google Scholar
• Kaplan MM. Medical progress: primary biliary cirrhosis. N Engl J Med 1987; 316: 521–8
   PubMed Web of Science ®Google Scholar
• Culp K S, Fleming C R, Duffy J, Baldus W P, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57: 365–70
   PubMed Web of Science ®Google Scholar
• Roll J, Boyer J L, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1–7
   PubMed Web of Science ®Google Scholar
• Neuberger J, Christensen E, Portman B, Caballeria J, Rodes J, Ranek L. Double-blind controlled trail of d-penicillamine in patients with primary biliary cirrhosis. Gut 1985; 26: 114–9
   PubMed Web of Science ®Google Scholar
• Bodenheimer H C, Schaffner F, Sternlieb I, Klion F M, Vernale S, Pezzullo J. A prospective clinical trial of penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985; 5: 1139–42
   PubMed Web of Science ®Google Scholar
• Christensen E, Neuberger J, Crowe J, Altman D G, Popper H, Portman B. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Gastroenterology 1985; 89: 1084–90
   PubMed Web of Science ®Google Scholar
• Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991; 14: 990–3
   PubMed Web of Science ®Google Scholar
• Bachrach W H, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. II. Dig Dis Sci 1982; 27: 833–56
   PubMed Web of Science ®Google Scholar
• Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12–3
   PubMed Web of Science ®Google Scholar
• Keane R M, Gadacz T R, Munster A M, Birmingham W, Winchurch RA. Impairment of human lymphocyte function by bile salts. Surgery 1984; 95: 439–43
   PubMed Web of Science ®Google Scholar
• Galle P R, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486–91
   PubMed Web of Science ®Google Scholar
• Poupon R, Poupon R E, Calmus Y, Chretien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1987; 1: 834–6
   PubMed Web of Science ®Google Scholar
• Björkhem I, Falk O. Assay of the major bile acids in serum by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 1983; 40: 163–70
   Google Scholar
• Ewerth S, Angelin B, Einarsson K, Nilsell K, Björkhem I. Serum concentrations of ursodeoxycholic acid in portal venous and systemic venous blood of fasting humans as determined by isotope dilution-mass spectrometry. Gastroenterology 1985; 88: 126–33
   PubMed Web of Science ®Google Scholar
• Knodell R G, Ishak K G, Black W C, Chen T S, Craig R, Kaplowitz N. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–5
   PubMed Web of Science ®Google Scholar
• Reichard O, Glaumann H, Norkrans G, Wejstål R, Frydén A, Schvarcz R. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 1994; 14: 169–74
   PubMedGoogle Scholar
• Mattsson L, Weiland O, Glaumann H. Application of a histological scoring system for assessment of histological outcome in patients with chronic posttransfusion non A-non B hepatitis with or without antibodies to hepatitis C. Liver 1990; 10: 257–63
   PubMedGoogle Scholar
• Bradley JW. Distribution-free statistical tests. Prentice-Hall, London 1968; 68–86
   Google Scholar
• Odén A, Wedel H. Arguments for Fisher's permutation test. Ann Statistics 1975; 3: 518–20
   Web of Science ®Google Scholar
• Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hübner K, Hellestern A. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268–74
   PubMed Web of Science ®Google Scholar
• Poupon R E, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548–54
   PubMed Web of Science ®Google Scholar
• Heathcote E J, Cauch-Dudek K, Walker V, Bailey J R, Blendis L M, Ghent C N. The Canadian multicenter double-blind randomized controlled study of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149–56
   PubMed Web of Science ®Google Scholar
• Combes B, Carithers R L, Maddrey W C, Lin D, McDonald M F, Wheeler D E. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759–66
   PubMed Web of Science ®Google Scholar
• Turner I B, Myszor M, Mitchison H C, Bennett M K, Burt A D, James O FW. A two-year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994; 9: 162–8
   PubMed Web of Science ®Google Scholar
• Battezzati P M, Podda M, Bianchi F B, Naccarato R, Orlandi F, Surrenti C. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. J Hepatol 1993; 17: 332–8
   PubMed Web of Science ®Google Scholar
• Lindor K D, Dickson E R, Baldus W P, Jorgensen R A, Ludwig J, Murtaug P A. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284–90
   PubMed Web of Science ®Google Scholar
• Leuschner U, Güldtüna S, Imhof M, Hübner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994; 21: 624–33
   PubMed Web of Science ®Google Scholar
• Neuberger J M, Gunson B K, Buckels J AC, Elias E, McMaster P. Referral of patients with primary biliary cirrhosis for liver transplantation. Gut 1990; 31: 1069–72
   PubMed Web of Science ®Google Scholar
• Poupon R E, Poupon R, Balkau B, UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342–7
   PubMed Web of Science ®Google Scholar
• Heathcote E J, Lindor K D, Poupon R, Cauch-Dudek K, Dickson E R, Trout R. Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1995; 108: A1082
   Google Scholar
• Batta A K, Salen G, Arora R, Shefer S, Tint G S, Abron J. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989; 10: 414–9
   PubMed Web of Science ®Google Scholar
• Stiehl A, Rudolph G, Raedsch R, Möller B, Hopf U, Lotterer E. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990; 12: 492–7
   PubMed Web of Science ®Google Scholar
• Podda M, Ghezzi C, Battezzati P M, Bertolini E, Crosignani A, Petroni M L. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989; 12: 59S–65S
   Google Scholar
• Hwang S-J, Chan C-Y, Lee S-D, Wu J-C, Tsay S-H, Lo K-J. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J Gastroenterol Hepatol 1993; 8: 217–23
   PubMed Web of Science ®Google Scholar
• Vogel W, Kathrein H, Judmaier G, Braunsteiner H. Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid. Lancet 1988; 1: 1163
   PubMed Web of Science ®Google Scholar